Skip to main content

Published

Low-dose prednisolone and B vitamins for post-COVID-19 syndrome in Germany: the PreVitaCOV randomised clinical trial.
Gágyor I. eClinicalMedicine 2026;:https://doi.org/10.1016/j.eclinm.2026.104264.
[In a placebo-controlled trial of 310 adults with post-COVID syndrome, 28 days of low-dose prednisolone produced a small reduction in overall symptoms, mainly fatigue, but the benefit did not meet the threshold for clinical relevance. B vitamins provided no meaningful benefit. Adverse events were similar across groups, with no treatment-related serious events. Further research is needed to determine whether prednisolone has a useful clinical role.]
Freely available online

Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Community Clinics
General Practice
Staff Groups
Drug Therapy
Medic